ZA200610578B - Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy - Google Patents

Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy

Info

Publication number
ZA200610578B
ZA200610578B ZA200610578A ZA200610578A ZA200610578B ZA 200610578 B ZA200610578 B ZA 200610578B ZA 200610578 A ZA200610578 A ZA 200610578A ZA 200610578 A ZA200610578 A ZA 200610578A ZA 200610578 B ZA200610578 B ZA 200610578B
Authority
ZA
South Africa
Prior art keywords
upar
upa
urokinase
diagnosis
receptor
Prior art date
Application number
ZA200610578A
Other languages
English (en)
Inventor
Graham C Parry
Andrew P Mazar
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of ZA200610578B publication Critical patent/ZA200610578B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
ZA200610578A 2004-05-25 2005-05-25 Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy ZA200610578B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57389604P 2004-05-25 2004-05-25

Publications (1)

Publication Number Publication Date
ZA200610578B true ZA200610578B (en) 2009-09-30

Family

ID=35451457

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610578A ZA200610578B (en) 2004-05-25 2005-05-25 Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy

Country Status (16)

Country Link
US (1) US8101726B2 (enExample)
EP (1) EP1765397B1 (enExample)
JP (1) JP4890449B2 (enExample)
KR (1) KR20070047246A (enExample)
CN (1) CN101022830A (enExample)
AU (1) AU2005248400A1 (enExample)
CA (1) CA2568428C (enExample)
DK (1) DK1765397T3 (enExample)
ES (1) ES2398221T3 (enExample)
IL (1) IL179565A0 (enExample)
MX (1) MXPA06013709A (enExample)
PL (1) PL1765397T3 (enExample)
PT (1) PT1765397E (enExample)
RU (1) RU2006145905A (enExample)
WO (1) WO2005116077A2 (enExample)
ZA (1) ZA200610578B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109742A2 (en) * 2006-03-21 2007-09-27 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
US8105602B2 (en) * 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2730282A1 (en) * 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2352503B1 (en) * 2008-11-06 2017-07-19 University of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
BR112013016107A2 (pt) 2010-12-22 2017-04-04 Ifom Fond Inst Firc Di Oncologia Molecolare molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
US9867923B2 (en) 2011-05-09 2018-01-16 University Of Miami Reducing soluble urokinase receptor in the circulation
CN103930128A (zh) 2011-08-05 2014-07-16 意大利癌症研究基金会分子肿瘤学研究所(Ifom) 组成型活性uPAR变体及其在抑制性抗体的生成与分离中的应用
KR102268883B1 (ko) * 2013-03-15 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US10681506B1 (en) 2018-04-19 2020-06-09 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
US10959062B1 (en) 2018-04-19 2021-03-23 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
WO2020055812A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
CA3114176A1 (en) * 2018-09-28 2020-04-02 Jochen Reiser Supar and prediction and treatment of acute kidney injury
EP4051714A4 (en) * 2019-10-28 2023-11-22 Monash University ANTIBODIES FOR BINDING PLASMIN
CN115867570A (zh) * 2020-06-15 2023-03-28 莫诺帕医疗公司 精确放射免疫治疗靶向尿激酶纤溶酶原激活剂受体（uPAR）以治疗严重COVID-19疾病
WO2022204267A1 (en) 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
EP4341265A4 (en) * 2021-05-21 2025-07-23 Northstar Medical Tech Llc TRIVALENT RADIOISTOPE BIO-TARGETED RADIOPHARMACEUTICAL, METHODS OF PREPARATION AND USE
CN117715648A (zh) * 2021-06-11 2024-03-15 纪念斯隆-凯特琳癌症中心 靶向uPAR的抗原识别受体和其用途
CA3246325A1 (en) * 2022-03-24 2023-09-28 The United States Government As Representative By The Department Of Veterans Affairs Urokinase-type plasminogen activator receptor-binding peptides and methods of use
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
DE10117381A1 (de) * 2001-04-06 2002-10-10 Wilex Biotechnology Gmbh Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke
WO2003079974A2 (en) * 2002-03-18 2003-10-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Integrin ligand
US8105602B2 (en) * 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Also Published As

Publication number Publication date
KR20070047246A (ko) 2007-05-04
IL179565A0 (en) 2007-05-15
CN101022830A (zh) 2007-08-22
CA2568428A1 (en) 2005-12-08
PT1765397E (pt) 2013-02-04
EP1765397A4 (en) 2009-05-13
WO2005116077A3 (en) 2005-12-29
WO2005116077A2 (en) 2005-12-08
MXPA06013709A (es) 2008-01-16
US20090180952A1 (en) 2009-07-16
EP1765397B1 (en) 2012-10-24
JP4890449B2 (ja) 2012-03-07
RU2006145905A (ru) 2008-06-27
JP2008509086A (ja) 2008-03-27
AU2005248400A1 (en) 2005-12-08
US8101726B2 (en) 2012-01-24
PL1765397T3 (pl) 2013-04-30
CA2568428C (en) 2020-12-29
EP1765397A2 (en) 2007-03-28
ES2398221T3 (es) 2013-03-14
DK1765397T3 (da) 2013-02-04

Similar Documents

Publication Publication Date Title
ZA200610578B (en) Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
AU2003278807A8 (en) KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1572724A4 (en) KDR AND VEGF / KDR BINDING SPEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
SG10201608268RA (en) Human antibodies that bind cxcr4 and uses thereof
IL209951A (en) Use of n-butyl-dioxinogirimycin and enzyme replacement therapy to make a drug for the treatment of pomp
WO2008125116A3 (en) Upar inhibition
IL174047A0 (en) Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
GB0523576D0 (en) Drug composition and its use in therapy
IL181126A0 (en) Preparation of gold-containing nano-liposome particles and their use in medical therapy
EP1874800A4 (en) DIAGNOSTIC AND THERAPEUTIC AGENTS
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
AU2003227148A8 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
GB201020621D0 (en) Pin for hygienic and/or medical use in the anal region
IL197509A0 (en) Therapeutic and/or ameliorating agent for disseminated intravascular coagulation
EP1721616A4 (en) TREATMENT AND FOOD TO TREAT TIREDNESS
EP1984734B8 (en) Sigma-2 receptor, method of screening of specific ligands and use of the same in diagnostic or therapeutic methods
IL177951A0 (en) Combination therapy including azd2171 and a platinum anticancer agent
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
WO2008095995A8 (en) Peptidic and non peptidic ligands for immunodetection of the receptor for urotensin ii
EP1944039A4 (en) ACTIVE AGENT FOR THE TREATMENT OF TUMORS AND ITS USE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS
EP1997487A4 (en) PRODUCT USED IN THE PREVENTION AND TREATMENT OF CARDIAC DISEASES, CANCER AND INFLAMMATORY DISEASES
GB0602110D0 (en) Use of ultrasound in the diagnosis and treatment of multiple sclerosis
EP1807067A4 (en) SPHINGOSINKINASE ACTIVATOR AND TREATMENT AGENT FOR SKIN DISEASES THEREWITH